MERCK KGAA

Merck KGaA lifts its voting‑rights stake to 8%, meeting German disclosure rules—no control shift, just transparent ownership for investors.

Merck KGaA’s July 2026 stock dip reveals how its robust patent strategy, digital‑health investments, and strong cash flow position it to beat rising EU pricing pressures and stay ahead in oncology and metabolic markets.

Merck’s $11 bn Bio‑Techne buy‑out boosts its omics, analytical and biotherapeutic portfolio, sparking a share rally and reinforcing its DAX leadership.

Merck’s $11 B cash takeover of Bio‑Techne fuels a surge in U.S. healthcare equity, revealing how strategic M&A, cost‑efficiency, and patient access shape tomorrow’s pharma landscape.

Merck KGaA tops expectations with oncology‑driven earnings, leveraging incremental indication expansion and lifecycle management to outpace peers like Eli Lilly and Amgen.

Merck KGaA’s latest earnings reveal how strong revenue visibility, supply agreements, and strategic acquisitions—like Bio‑Techne—enable pharma to navigate patent cliffs, market access, and high‑growth oncology pipelines while safeguarding margins.

Merck KGaA’s June 26 market dip masks a strategic gain: a Bio‑Techne acquisition and robust oncology/mRNA pipeline signal long‑term growth amid sector volatility.

Merck KGaA’s €10 bn acquisition of Bio‑Techne unlocks €200 m annual cost savings, 12 % EPS boost and a high‑margin analytics edge, redefining life‑science consolidation.

Merck KGaA’s shares stay solid in the DAX, backed by transparent voting rights and a strong pipeline of targeted therapies that promise future growth.

Merck partners with Saturnus Bio to develop RNA‑ and CRISPR‑based gene‑modulation therapies for rare genetic cardiomyopathies, aiming for faster, more precise treatments.